The carrying amount of goodwill at June 30, 2019 and March 31, 2019 was $33.0 million and $32.6 million, respectively, and has been recorded in connection with the Company’s acquisition of Impella Cardiosystems AG, in May 2005 and ECP and AIS in July 2014. The carrying value of goodwill and the change in the balance for the three months ended June 30, 2019 are as follows:

	(in $000's)
Balance, March 31, 2019	$	32,601
Foreign currency translation impact		434
Balance, June 30, 2019	$	33,035

The Company evaluates goodwill at least annually at October 31, as well as whenever events or changes in circumstances suggest that the carrying amount may not be recoverable. The Company has no accumulated impairment losses on goodwill.

The carrying amount of in-process research & development, or IPR&D, assets at June 30, 2019 and March 31, 2019 was $15.4 million and $15.2 million, respectively, and was recorded in conjunction with the Company’s acquisition of ECP and AIS, in July 2014. The estimated fair value of IPR&D assets at the acquisition date was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flow estimates for the future Impella ECP^TM expandable catheter pump technology were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the acquisition date and the time and resources needed to complete development. The Company used an original discount rate of 21% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.

The carrying value of the Company’s IPR&D assets and the change in the balance for the three months ended June 30, 2019 are as follows:

	(in $000's)
Balance, March 31, 2019	$	15,208
Foreign currency translation impact		203
Balance, June 30, 2019	$	15,411

The Company evaluates IPR&D assets at least annually at October 31, as well as whenever events or changes in circumstances suggest that the carrying amount may not be recoverable. The Company has no accumulated impairment losses on IPR&D assets.

	June 30, 2019		March 31, 2019
	(in $000's)
Other investments	$	122,433	$	80,779
Right of use asset - lease (Note 8)		13,234		—
Other intangible assets and other		5,153		4,336
Total other assets	$	140,820	$	85,115

The Company periodically makes investments in medical device companies that focus on heart failure, heart pump and other medical device technologies. The Company measures investments in equity securities at fair value and recognize changes in fair value in net income. For investments in convertible debt or preferred stock securities that do not have readily determinable market values, the Company measures these investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment. The Company monitors any events or changes in circumstances that may have a significant effect on the fair value of investments, either due to impairment or based on observable price changes, and makes any necessary adjustments.

The carrying value of the Company’s portfolio of other investments and the change in the balance for the three months ended June 30, 2019 and 2018 are as follows:

	For the Three Months Ended June 30,
		2019		2018
	(in $000's)
Beginning balance	$	80,779	$	12,649
Additions		2,000		1,166
Disposals		—		—
Change in fair value, net		39,654		—
Ending balance	$	122,433	$	13,815

In fiscal 2019, the Company invested $25.0 million in Shockwave Medical. The fair value of this investment included within Other investments as of June 30, 2019 and March 31, 2019 was $95.8 million and $56.2 million, respectively. During the three months ended June 30, 2019, the Company recognized a pre-tax unrealized gain of $39.7 million on its investment in Shockwave Medical. During the three months ended June 30, 2019 the Company made investments of $2.0 million in other medical device companies.

Included within other intangible assets and other is $3.6 million related to license manufacturing rights to certain technology from third parties. These intangible assets are classified with other assets in the Company’s consolidated balance sheet and are amortized over their useful life of 15 years.